Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$173.9M
+18.5% from 2023
Prescriptions
14K
$12,783.35 per claim
Patients
2,439
2,248 prescribers
Total spending, 2024
$173.9M
$71,267.71 per patient
Medicare prescription drug plans paid $173.9M for Tafinlar in 2024, for 13,602 prescriptions and refills to 2,439 patients (up 18.5% from 2023). The average cost per claim was $12,783.35.
California had the highest Medicare cost for Tafinlar in 2024: $24.6M for 1,952 claims, followed by Texas ($15.5M).
Eric J Sherman, medical oncology in Philadelphia, PA, had the highest Medicare cost for Tafinlar in 2024: 142 claims costing $2.0M.
Tafinlar is made by Novartis AG (NVS), listed in the Medicare spending data as Novartis.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Eric J Sherman Philadelphia, PA | Medical Oncology | 142 | 25 | $2.0M |
| Mabel M Ryder Rochester, MN | Endocrinology | 78 | 14 | $968K |
| Michael M Buljan |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 2,027 | 12,122 | 2,171 | $137.4M |
| 2023 | 2,008 | 11,692 | 2,117 | $146.8M |
| 2024 | 2,248 | 13,602 | 2,439 | $173.9M |
Amount reimbursed by state Medicaid programs, all states
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Nurse Practitioner |
| 58 |
| Under 11 |
| $720K |
| Nabil F Saba Atlanta, GA | Medical Oncology | 51 | Under 11 | $709K |
| Priyanka C Iyer Houston, TX | Endocrinology | 56 | Under 11 | $707K |
| Maria E Cabanillas Houston, TX | Endocrinology | 51 | 12 | $683K |
| Victoria M Villaflor Orange, CA | Medical Oncology | 55 | 12 | $671K |
| Ramona Dadu Houston, TX | Endocrinology | 54 | Under 11 | $645K |
| Naifa L Busaidy Houston, TX | Endocrinology | 56 | Under 11 | $620K |
| James W Smithy New York, NY | Medical Oncology | 44 | Under 11 | $588K |
| Siddharth H Sheth Pittsburgh, PA | Internal Medicine | 46 | Under 11 | $487K |
| Kin Wai Hung Hartford, CT | Medical Oncology | 35 | Under 11 | $450K |
| Ahmed M Abdelaziz Tucson, AZ | Hematology-Oncology | 32 | Under 11 | $448K |
| Kathleen C Kerrigan Columbus, OH | Hematology-Oncology | 31 | Under 11 | $441K |
| Vineeth K Sukrithan Columbus, OH | Medical Oncology | 32 | Under 11 | $428K |
| Parisa Momtaz West Harrison, NY | Hematology-Oncology | 30 | Under 11 | $424K |
| David E Marinier La Crosse, WI | Hematology-Oncology | 35 | Under 11 | $408K |
| Mimi I Hu Houston, TX | Endocrinology | 29 | Under 11 | $405K |
| Sandeep H Mashru Portland, OR | Hematology-Oncology | 32 | Under 11 | $403K |
| Arvinda Padmanabhan Lexington, KY | Medical Oncology | 28 | Under 11 | $397K |
| Ahmad A Al-Hader Indianapolis, IN | Internal Medicine | 27 | Under 11 | $395K |
| Andrew L Pecora Hackensack, NJ | Hematology-Oncology | 32 | Under 11 | $395K |
| Meetal Dharia Los Angeles, CA | Nurse Practitioner | 31 | Under 11 | $392K |
| Kristen M Burkett Westwood, KS | Nurse Practitioner | 43 | Under 11 | $389K |
| Conor E Steuer Atlanta, GA | Hematology-Oncology | 28 | Under 11 | $385K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Novartis NVS | 13,603 | $173.9M |